Our ClearCell® FX1 System is a fully automated device for cell retrieval that can separate and enrich wholly intact and viable circulating tumour cells, or CTCs from small amounts of blood. It is driven by our CTChip®FR1 biochip, which is a single-use microfluidic biochip.
- Label-Free enrichment
- Recovers heterogeneous populations of CTCs
- Ready integration to various downstream applications
- Continuous sample flow
- Intact and viable cells
- Automated system
- Consistent and reproducible
- Fast processing time
How it Works
A blood sample is obtained from a patient through a simple blood draw. We first chemically treat the blood sample to lyse (break down) and remove the red blood cells. The sample is then passed through the CTChip® FR1 biochip to isolate the CTCs from leukocytes (white blood cells).
Our ClearCell® FX1 System has been tested and validated for use with human blood samples. The choice of blood collection tube depends on the intended downstream application, or diagnostic test. Our recommenced blood collection tubes to use with the ClearCell® FX1 System includes the Streck Cell-free DNA BCT® and EDTA tubes.
CTC Analysis & Downstream Assays
- Immunofluorescence
- Characterisation of CTC
- Cytopathology
- Examination of cell manifestation status at microscope level
- Cytogenetics
- FISH; Detection of genetic anomaly
- Cell culture
- Experimental therapeutics
- Genomics
- DNA/RNA genetic analysis
The wholly intact and viable CTCs isolated using our ClearCell® FX1 System are collected in a liquid suspension and can be transferred to various formats, such as glass slides and microtiter plates, for easy integration with routine pathology laboratory workflows. The potential downstream applications of the CTCs isolated using our ClearCell® FX1 System include the following:
Immunofluorescence
Fluorescently-labelled antibodies specific to CTCs and leukocytes can be used to identify and enumerate CTCs or detect cancer-specific biomarkers.
CTC counts provide prognostic information, particularly, the metastatic aggressiveness of the tumour. An increase in CTC counts may suggest tumour relapse after therapeutic intervention.
Fluorescent in situ hybridization (FISH)
CTCs isolated using our ClearCell® FX1 System can be analysed using fluorescent in situ hybridisation ("FISH"), a technique that allows pathologists to identify chromosomal abnormalities in cells, including gene translocation, amplification and deletions.
In a FISH assay, fluorescent probes (labelled fragments of DNA or RNA) that bind to specific nucleotide sequences in chromosomes are applied to the CTCs. The presence or absence of specific nucleotide sequences is detected by noting the location and counts of fluorescent dots after the probes have been applied.
FISH can be used to detect ALK gene rearrangement in lung cancer patients and HER2 gene amplification in breast cancer patients, in order to help physicians identify patients that are suitable for ALK and HER2 targeted drug therapies (for example, the drug Crizotinib targets ALK in lung cancer patients and the drug Trastuzumab targets HER2 in breast cancer patients).
Genetic Analysis
Gene mutations and aberrant gene expression are commonly found in cancer cells.
Some cancer mutations are drug-actionable targets that can be used to select effective treatment strategies. An example would be the detection of BRAF V600E mutation in melanoma (skin cancer) patients, which can be targeted by the drug Vemurafenib.
In vitro or in vivo tumour models
As the CTCs isolated using our ClearCell® FX1 System have high integrity and viability, they can be cultured in vitro for cancer R&D of novel therapeutics.
In addition, CTCs can be implanted into animal models (patient-derived xenografts) that can be used to screen for suitable drugs by monitoring tumour size and spread in the host animal.
